Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.46 |
| ▸ | MAPKAPK5 | Q8IW41 | 3/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922413 | 0.89 | MAPKAPK5 (0.42) | MAPKAPK5MT-CO2FYNSYK | |
| SCHEMBL1685200 | 0.88 | MAPKAPK5 (0.58) | JAK2MAPKAPK5FYNSYK | |
| SCHEMBL12618527 | 0.88 | JAK2 (0.57) | JAK2MAPKAPK5JAK3FYN | |
| SCHEMBL13922443 | 0.85 | SYK (0.41) | MAPKAPK5FYNSYK | |
| SCHEMBL12618574 | 0.85 | JAK2 (0.43) | JAK2MAPKAPK5JAK3FYNSYK | |
| SCHEMBL13922454 | 0.84 | RAD52 (0.47) | MAPKAPK5MT-CO2FYNSYK | |
| SCHEMBL13922273 | 0.83 | SYK (0.42) | MAPKAPK5MAPTGAAFYNSYK | |
| SCHEMBL13922252 | 0.83 | SYK (0.41) | MAPKAPK5MT-CO2FYNSYK | |
| SCHEMBL12619248 | 0.83 | SYK (0.42) | MAPKAPK5FYNSYK | |
| SCHEMBL12618764 | 0.83 | JAK2 (0.43) | JAK2MAPKAPK5MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N. V. (BE) | 2012-01-12 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-7951818-B2 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-05-31 | — | — | US | disclosed |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008065199-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010206-A1 | IMIDAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | COL2A1, MMP1, COL1A1 | JAK2 1510/4885MAPKAPK5 19/4885ESRRG 2937/4885 |
| US-20090048245-A1 | Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases | COL2A1, MMP1, COL1A1 | JAK2 1510/4885MAPKAPK5 19/4885ESRRG 2937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.